Dr Linda Mileshkin

Honorary Associate
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone 03 9656 1697

Map

Selected grants

2013

  • A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK trial; Mileshkin L, Narayan K, Rischin D, Quinn M, Friedlander M, Moore K, Kitchener H, Shrivastava S, Martyn J, Small Jnr W; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer; Mileshkin L, Quinn M, Khaw P, Stockler M, Brand A, Martyn J, Sjoquist K, Creutzberg C; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Bonaventura, A., O'Connell, R., Mapagu, C., Beale, P., McNally, O., Mileshkin, L., Grant, P., Hadley, A., Goh, J., Sjoquist, K., Martyn, J., deFazio, A., et al (2017). Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer. International Journal of Gynecological Cancer, 27(5), 900-906. [More Information]

2017

  • Bonaventura, A., O'Connell, R., Mapagu, C., Beale, P., McNally, O., Mileshkin, L., Grant, P., Hadley, A., Goh, J., Sjoquist, K., Martyn, J., deFazio, A., et al (2017). Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer. International Journal of Gynecological Cancer, 27(5), 900-906. [More Information]

To update your profile click here. For support on your academic profile contact .